{"analyses":[{"ciLowerLimit":"0.369","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.555","groupDescription":"Hazard ratio and its 95% CI was based on stratified (IVRS) Cox Regression Model. One-sided p-value was calculated from log rank test and 95% CIs was computed by using Cox Regression Model.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"< 0.000001","paramType":"Hazard Ratio (HR)","paramValue":"0.453","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.397","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.580","groupDescription":"Hazard ratio and its 95% CI was based on unstratified Cox Regression Model. One-sided p-value was calculated from log rank test and 95% CIs was computed by using Cox Regression Model.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"< 0.000001","paramType":"Hazard Ratio (HR)","paramValue":"0.480","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.347","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.522","groupDescription":"Hazard ratio and its 95% CI was based on stratified (IVRS) Cox Regression Model. One-sided p-value was calculated from log rank test and 95% CIs was computed by using Cox Regression Model.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"< 0.000001","paramType":"Hazard Ratio (HR)","paramValue":"0.425","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.376","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.548","groupDescription":"Hazard ratio and its 95% CI was based on unstratified Cox Regression Model. One-sided p-value was calculated from log rank test and 95% CIs was computed by using Cox Regression Model.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"< 0.000001","paramType":"Hazard Ratio (HR)","paramValue":"0.454","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"44","spread":"44","upperLimit":"47","value":"45"},{"groupId":"OG001","lowerLimit":"86","spread":"86","upperLimit":"127","value":"95"}]}],"title":"mRECIST"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"44","spread":"44","upperLimit":"49","value":"45"},{"groupId":"OG001","lowerLimit":"87","spread":"87","upperLimit":"127","value":"102"}]}],"title":"RECIST 1.1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"194"},{"groupId":"OG001","value":"379"}],"units":"Participants"}],"description":"Progression Free Survival (PFS) was defined as the time (days) from date of randomization to date of disease progression (radiological or clinical) or death due to any cause, if death occurs before progression was documented. Death in the absence of progression was a PFS event only if it occurred within the 12+1 weeks for subjects who discontinued treatment prior to cycle 8 and 24+2 weeks for subjects who discontinued treatment after to cycle 8 of the last evaluable tumor assessment; PFS were censored at the date of the last evaluable tumor assessment, if it occurred later. Median and 95% confidence interval 95% were reported for the mRECIST and RECIST 1.1 analysis sets. Subjects still alive at the time of analysis were censored at their last date of last contact.","dispersionType":"95% Confidence Interval","groups":[{"description":"Subjects received placebo matched to regorafenib coated tablets orally every day for 3 weeks followed by 1 week off treatment plus best best supportive care.","id":"OG000","title":"Placebo"},{"description":"Subjects received regorafenib 160 milligram (mg) (4 \\* 40 mg coated tablets) orally every day for 3 weeks followed by 1 week off treatment plus BSC.","id":"OG001","title":"Regorafenib 160 mg (BAY73-4506)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From date of randomization until 30 days after last study treatment (assessed every 6 weeks until PD; and after 8 cycle assessed every 12 weeks)","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"days"}